Navigation Links
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
Date:2/7/2013

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

"We were able to demonstrate that this applied across all patients and that those who had the greatest benefit from the drug while it was administered retained this benefit," says senior author Dr. Tito Fojo, of the National Cancer Institute at the National Institutes of Health.

Sunitinib, which is approved around the world for the treatment of several different cancers, works by targeting proteins on the blood vessels that feed tumors. Animal studies have suggested that treatment with sunitinib may induce changes in tumor vessels or adaptations within tumors themselves that could promote cancer growth and spread.

When Dr. Fojo and his colleagues analyzed more than 10,000 data points from the pivotal randomized phase 3 clinical trial that led to sunitinib's approval, the evidence clearly showed that no matter how long patients took sunitinib, it was not harmful, did not accelerate tumor growth, and did not shorten survival after treatment ended. During treatment, the drug slowed tumor growth and prolonged the patients' survival.

"Last year, I was approached by two patients who had grave concerns about taking sunitinib due to an article conducted in animals. I realized that if clinical data exist that refute basic science, they must be published," recalls Dr. Fojo.

The researchers' findings indicate that sunitinib can benefit patients without altering tumor biology after the drug is stopped. "We hope this can be generalized to similar drugs but recognize that further studies will be needed," says first author Dr. Krastan Blagoev of the National Science Foundation. "Nevertheless, other drugs also approved worldwide for a variety of cancersincluding sorafenib, pazopanib, and axitinibare similar to sunitinib, and this will give some reassurances that one need not expect things to get worse after such drugs are discontinued."


'/>"/>

Contact: Mary Beth OLeary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert  

Related medicine news :

1. Potential new technique for anticancer radiotherapy could provide alternative to brachytherapy
2. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
3. Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
4. Fat Loss 4 Idiots: Review Examining New "Accelerated Fat Loss Diet" Released By DietsAndFitnessGuides.com
5. EzW2 Software From Halfpricesoft.com Updated To Accelerate Tax Reporting For Startups
6. Studying marrow, URMC researchers accelerate blood stem cells
7. Topical simvastatin shown to accelerate wound healing in diabetes
8. Concussions and head impacts may accelerate brain aging
9. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
10. Higher energies for laser-accelerated particles possible
11. Accelerated radiation treatment effective for noninvasive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... , ... February 12, 2016 ... ... today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced ... will recruit top students from U.S. universities who will draw from Siemens’ ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... CHAPEL HILL, N.C. , Feb. 12, 2016  Clinical Affairs ... their clinical presence in emerging areas of the world. While some ... regions, others lag in their clinical activity in countries such as ... China and India ... approvals to market products in those countries. --> ...
(Date:2/12/2016)... , Feb. 12, 2016   National Community Pharmacists ... RPh, MBA issued the following statement today in response ... by the Centers for Medicare & Medicaid Services ... NCPA, beneficiary advocates and others: patient advocacy ... are still reviewing the full CMS analysis. Our initial ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
Breaking Medicine Technology: